EGFR-TK Inhibitor
Sponsors
Shanghai Pulmonary Hospital, Shanghai, China, Zaiwen Fan, LuBing, Xinqiao Hospital of Chongqing, Instituto Oncológico Dr Rosell
Conditions
Advanced CancerBrain MetastasesCarcinoma, Adenoid CysticCarcinoma, Non-Small-Cell LungEGFR Gene MutationLung Cancer, Nonsmall CellNon Small Cell Lung CancerNon-Small Cell Lung Cancer
Phase 1
Phase 2
EGFR-TKI With/Without Chemotherapy in NSCLC Patients With Both EGFR Mutation and BIM Deletion Polymorphism
NCT03002844
Start: 2016-12-31End: 2018-12-31Target: 50Updated: 2016-12-28
Anti-angiogenesis Combine With EGFR-TKI in Advanced Non-squamous Non Small Cell Lung Cancer
NCT03461185
Start: 2018-05-01End: 2020-02-20Target: 100Updated: 2018-03-09
Tyrosine Kinase Inhibitors in Metastastic Adenoid Cystic Carcinoma
RecruitingNCT04974866
Start: 2021-07-01End: 2026-07-31Target: 20Updated: 2023-03-29
SRS for NSCLC With Oligo-residual Intracranial Disease After First-line 3rd Generation EGFR-TKI
Active, not recruitingNCT06020066
Start: 2023-08-10End: 2028-08-10Updated: 2025-09-15